Page last updated: 2024-08-22

trimetazidine and fluorodeoxyglucose f18

trimetazidine has been researched along with fluorodeoxyglucose f18 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Borra, R; Bucci, M; Del Ry, S; Giannessi, D; Iozzo, P; Knuuti, J; Maggio, R; Någren, K; Nuutila, P; Oikonen, V; Parkkola, R; Rigazio, S; Taittonen, M; Tuunanen, H; Viljanen, T	1

Trials

1 trial(s) available for trimetazidine and fluorodeoxyglucose f18

Article	Year
Human obesity is characterized by defective fat storage and enhanced muscle fatty acid oxidation, and trimetazidine gradually counteracts these abnormalities. American journal of physiology. Endocrinology and metabolism, 2011, Volume: 301, Issue:1 Topics: Adult; Aged; Anti-Obesity Agents; Cross-Sectional Studies; Fats; Fatty Acids; Fluorodeoxyglucose F18; Humans; Lipid Metabolism; Middle Aged; Muscle, Skeletal; Obesity; Oxidation-Reduction; Positron-Emission Tomography; Trimetazidine; Up-Regulation; Vasodilator Agents; Young Adult	2011

Article

Year

Human obesity is characterized by defective fat storage and enhanced muscle fatty acid oxidation, and trimetazidine gradually counteracts these abnormalities.

American journal of physiology. Endocrinology and metabolism, 2011, Volume: 301, Issue:1

Topics: Adult; Aged; Anti-Obesity Agents; Cross-Sectional Studies; Fats; Fatty Acids; Fluorodeoxyglucose F18; Humans; Lipid Metabolism; Middle Aged; Muscle, Skeletal; Obesity; Oxidation-Reduction; Positron-Emission Tomography; Trimetazidine; Up-Regulation; Vasodilator Agents; Young Adult

2011